Clik here to view.
Senseonics prices $50m notes offering, touts Q4 and full-year prelims
Senseonics (NYSE:SENS) announced today an underwritten offering of $50 million in 5.25% convertible senior notes due 2023, alongside a 30-day option for underwriters to buy up to an additional $7.5...
View ArticleClik here to view.
Senseonics’ implantable glucose monitor succeeds in 90-day trial
A 90-day trial involving patients with Type I and Type II diabetes showed that Senseonics‘ (NYSE:SENS) implantable continuous glucose monitor was safe and accurate compared to reference glucose values,...
View ArticleClik here to view.
FDA panel to review Senseonics’ implantable CGM this month
A panel for the FDA is slated to review Senseonics‘ (NYSE:SENS) premarket approval application for its Eversense implantable continuous glucose monitoring system on March 29. The company’s device sends...
View ArticleClik here to view.
Senseonics tops Q4 EPS estimates, misses sales expectations
Shares in Senseonics (NYSE:SENS) closed down -3% yesterday after the medical device maker met earnings expectations on Wall Street with its fourth quarter and full-year financial results, but narrowly...
View ArticleClik here to view.
FDA committee backs Senseonics’ implantable continuous glucose monitor
An FDA advisory panel voted unanimously to recommend approval for Senseonics‘ (NYSE:SENS) implantable continuous glucose monitor, Eversense, the company touted this week. The panel of medical experts...
View ArticleClik here to view.
Senseonics Q1 misses on EPS
Shares in Senseonics (NYSE:SENS) have fallen slightly today after the continuous glucose monitoring-focused medtech company posted first quarter earnings that missed on earnings per share expectations...
View ArticleClik here to view.
Beta Bionics taps Senseonics’ implantable glucose monitor for artificial...
Senseonics‘ (NYSE:SENS) said today that it inked a deal to integrate glucose data from its Eversense continuous glucose monitoring system into Beta Bionics‘ investigational iLet bionic pancreas....
View ArticleClik here to view.
FDA approves Senseonics’ implantable continuous glucose monitor
The FDA this week approved Senseonics‘ (NYSE:SENS) Eversense continuous glucose monitor for use in people ages 18 and older with diabetes. The device is the first CGM system to feature an implantable...
View ArticleClik here to view.
Senseonics prices $130m public offering
On the heels of an FDA approval for its implantable continuous glucose monitoring tech, Senseonics‘ (NYSE:SENS) today priced a $130 million underwritten public offering of common stock. The offering,...
View ArticleClik here to view.
Senseonics closes $150m public offering
Senseonics (NYSE:SENS) said today that it closed an underwritten public offering of its common stock, reeling in $149.5 million in total proceeds. The Germantown, Md.-based company plans to use its...
View ArticleClik here to view.
Senseonics inks diabetes management deal with Glooko
Senseonics (NYSE:SENS) said today that it inked a global deal to integrate its Eversense continuous glucose monitoring system with Glooko‘s diabetes data management tech. Users will be able to sync...
View ArticleClik here to view.
Senseonics launches Eversense implantable glucose monitor
Senseonics (NYSE:SENS) said today that its Eversense continuous glucose monitoring system is available at clinics across the U.S. The Germantown, Md.-based company also touted that it won coverage for...
View ArticleClik here to view.
Senseonics wins coverage from Aetna for Eversense glucose monitor
Senseonics (NYSE:SENS) said this week that won coverage from health plan provider Aetna for its Eversense continuous glucose monitoring system. Aetna provides coverage for roughly 22 million people in...
View ArticleClik here to view.
Senseonics wins another FDA approval for its implantable CGM
Senseonics (NYSE:SENS) said this week that it won another FDA approval for its implantable continuous glucose monitoring system, giving nurse practitioners and physicians assistants the ability to...
View ArticleClik here to view.
Senseonics reports mixed Q3 results
Shares in Senseonics (NYSE:SENS) fell today after the medical device maker missed EPS expectations but met sales estimates on Wall Street with its third quarter financial results. The Germantown,...
View ArticleClik here to view.
Senseonics CFO Elsey to retire | Personnel Moves – December 4, 2018
Senseonics (NYSE:SENS) said yesterday that its CFO R. Elsey is retiring for the company, and that it has begun searching for a permanent replacement. The Germantown, Md.-based company said that Elsey...
View ArticleClik here to view.
Senseonics touts first U.S. trial implant of 180-day CGM
Senseonics (NYSE:SENS) said yesterday that its Eversense XL 180-day continuous glucose sensor was implanted into the first participant of a trial designed to support a pre-market application to the...
View ArticleClik here to view.
Insulet taps former Medtronic finance exec McMillan as CFO | Personnel Moves...
Insulet (NSDQ:PODD) said yesterday that it tapped former Medtronic minimally invasive therapies CFO and finance VP Wayde McMillan as its new chief financial officer, replacing Michael Levitz. The...
View ArticleClik here to view.
Senseonics wins MRI-safe FDA nod for Eversense CGM
Senseonics announced that it has received notice from the FDA that its Eversense sensor no longer has to be removed for MRI scanning. “Based on our testing, we have demonstrated hat it is safe for...
View ArticleClik here to view.
Senseonics extends distribution agreement with Roche Diabetes Care
Senseonics Holdings (NYSE-American: SENS) — maker of an implantable continuous glucose monitoring system for people with diabetes — has extended its distribution agreement with Roche Diabetes Care. The...
View ArticleClik here to view.
Senseonics partners to provide veterans with Eversense CGM
Senseonics (NYSE:SENS) this week announced that it partnered with Geo-Med to provide access to the Eversense continuous glucose monitor to more than 9 million veterans and U.S. government staff. The...
View ArticleClik here to view.
Senseonics inks CGM data deal with Glooko
Senseonics (NYSE:SENS) said today that data from its Eversense continuous glucose monitoring system can be integrated into Glooko‘s diabetes data management tech. Thanks to the new partnership,...
View ArticleClik here to view.
HydroCision names Tranchemontagne as CEO | Personnel Moves – March 12, 2019
HydroCision said early this month that it tapped former Smith & Nephew (NYSE:SNN) exec Alain Tranchemontagne as its new chief executive officer. Prior to joining Boston-based HydroCision,...
View ArticleClik here to view.
Senseonics shares dip on Q4 sales miss, lowered guidance
Shares in Senseonics (NYSE:SENS) fell slightly today after the diabetes-focused device maker posted fourth quarter and full year 2018 earnings that beat loss-per-share consensus but missed sales...
View ArticleClik here to view.
Senseonics touts patient access program for Eversense CGM
Senseonics (NYSE:SENS) said today that it launched the Eversense Bridge Program, which is designed to improve patient access to Senseonics’ Eversense continuous glucose monitoring system. The company...
View Article